Perrigo Company plc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
Perrigo Company plc (PRGO) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $184.50 million as of 2017-04-01, per its 10-Q filed 2017-05-30.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2017-05-30
- 2017-04-01: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $184.50M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2017-04-01 | $184.50M 10-Q · filed 2017-05-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |